Madeleine Duvic, M.D.
Department of Dermatology, Division of Internal Medicine
About Dr. Duvic
Madeleine Duvic, M.D., I went to Duke to become a clinician scientist interested in T-cell immunology and in translational research. My goal is to understand the pathogenesis of T-cell mediated skin diseases in order to develop novel targeted therapy. I have collaborated with pharmacology to develop protocols and then conduct clinical trials that lead to the registration of new FDA approved agents for cutaneous T-cell lymphoma that include bexarotene (first rexinoid), denileukin diftitox (first targeted fusion toxin), and vorinostat (first histone deacetylase inhibitor). In addition to directing an NIH funded molecular biology lab and a clinical trials research team, I personally have cared for over 2,000 MD Anderson cutaneous T-cell lymphoma patients. I belong to the UT graduate school immunology program. As a past recipient of a K24 award in cutaneous oncology, I continue to actively mentor research fellows, residents, PhDs, and medical students.
Present Title & Affiliation
Primary Appointment
Deputy Department Chair, Department of Dermatology, Division of Internal Medicine, UTMDACC, Houston, TX
Professor of Medicine and Dermatology (with tenure), Division of Internal Medicine, UTMDACC, Houston, TX
Blanche Bender Professorship in Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of Division of Epidemiology, Human Genetics & Environmental Sciences, The University of Texas School of Public Health, Houston, TX
Professor of Medicine and Dermatology, Department of Dermatology, The University of Texas Medical School at Houston (UTMSH), Houston, TX
Clinical Interests
- Cutaneous lymphomas and Sezary syndrome
- Skin cancer and melanoma
Education & Training
Degree-Granting Education
| 1977 | Duke University Medical School, Durham, NC, USA, MD, Medicine |
| 1973 | Rice University, Houston, TX, USA, BA, Biology |
Postgraduate Training
| 1984-1985 | Research Visiting Fellow, Molecular Genetics, Baylor College of Medicine, Houston, TX |
| 1982-1984 | Postdoctoral Fellowship, Molecular Genetics & Geriatrics, Duke University, Durham, NC |
| 1981-1982 | Residency in Internal Medicine, Duke University, Durham, NC |
| 1979-1979 | Chief Resident, Dermatology, Duke University, Durham, NC |
| 1978-1980 | Residency in Dermatology, Duke University, Durham, NC |
| 1977-1978 | Internship in Internal Medicine, Duke University, Durham, NC |
Board Certifications
| 1982 | American Board of Internal Medicine |
| 1981 | American Board of Dermatology |
Honors & Awards
| 2018 | Gagel Career Achievement Award, UT MD Anderson Cancer Center |
| 2001 | America's Top Doctors, Castle Connolly Medical Ltd |
| 1994 | Best Doctors in America |
Selected Publications
Peer-Reviewed Articles
- Dummer R, Prince HM, Whittaker S, Horwitz SM, Kim YH, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown L, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Huen A, Walewski J, Wang Y, Lisano J, Richhariya A, Feliciano J, Zhu Y, Bunn V, Little M, Zagadailov E, Dalal MR, Duvic M. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: results from the randomised phase III ALCANZA study. Eur J Cancer 133:120-130, 2020. e-Pub 2020. PMID: 32502876.
- Morris L, Tran J, Duvic M. Non-Classic Signs of Sézary Syndrome: A Review. Am J Clin Dermatol 21(3):383-391, 2020. e-Pub 2020. PMID: 31953789.
- Anand K, Ensor J, Pingali SR, Hwu P, Duvic M, Chiang S, Miranda R, Zu Y, Iyer S. T-cell lymphoma secondary to checkpoint inhibitor therapy. J Immunother Cancer 8(1), 2020. PMID: 32114498.
- Ramachandran V, Park KE, Duvic M. Long-term control of mycosis fungoides of the hands with topical bexarotene: an update 15 years later. Int J Dermatol 58(11):e221-e222, 2019. e-Pub 2019. PMID: 31209865.
- Tetzlaff MT, Tang S, Duke T, Grabell DA, Cabanillas ME, Zuo Z, Yao JC, Nagarajan P, Aung PP, Torres-Cabala CA, Duvic M, Prieto VG, Huen A, Curry JL. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features. J Cutan Pathol 48(11):872-7, 2019. e-Pub 2019. PMID: 31254410.
- Ramachandran V, Park KE, Shah JR, Duvic M. Diagnosis of cutaneous T-cell lymphoma by insurance type before and after the Affordable Care Act: a national database study. Dermatol Online J 25(11), 2019. e-Pub 2019. PMID: 32045145.
- Lewis DJ, Wu JH, Boyd M, Duvic M, Feldman SR. Cutaneous manifestations of genodermatoses and primary immunodeficiency. Dermatol Online J 25(6), 2019. e-Pub 2019. PMID: 31329384.
- Kubicki SL, Park KE, Aung PP, Duvic M. Complete Resolution of Primary Cutaneous Anaplastic Large Cell Lymphoma With Topical Imiquimod. J Drugs Dermatol 18(5):460-462, 2019. PMID: 31141854.
- Ying Z, Shiue L, Park K, Kollet J, Bijani P, Goswami M, Duvic M, Ni X. Blood transcriptional profiling reveals IL-1 and integrin signaling pathways associated with clinical response to extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma. Oncotarget 10(34):3183-3197, 2019. e-Pub 2019. PMID: 31139332.
- Fountain E, Mistry H, Jain P, Duvic M, Fowler N. Response to Pembrolizumab and Lenalidomide in advanced refractory mycosis fungoides. Leuk Lymphoma 60(4):1-4, 2019. e-Pub 2018. PMID: 30301395.
- Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med 380(17):1628-1637, 2019. PMID: 31018069.
- Park K, Reed J, Talpur R, Duvic M. Nail irregularities associated with Sézary syndrome. Cutis 103(4):E11-E16, 2019. PMID: 31116823.
- Méhul B, Ménigot C, Fogel P, Seraidaris A, Genette A, Pascual T, Duvic M, Voegel JJ. Proteomic analysis of stratum corneum in Cutaneous T-Cell Lymphomas and psoriasis. Exp Dermatol 28(3):317-321, 2019. e-Pub 2019. PMID: 30637808.
- An Y, Jiang W, Andraos TY, Reddy JP, Yehia ZA, Lloyd S, Duvic M, D'Souza NM, Milgrom SA, Pinnix CC, Oki Y, Smith GL, Wilson LD, Dabaja BS. Multi-institutional investigation: circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. Radiother Oncol 131:88-92, 2019. e-Pub 2018. PMID: 30773193.
- Welborn M, Duvic M. Antibody-based therapies for cutaneous T-cell lymphoma. Am J Clin Dermatol 20(1):115-122, 2019. e-Pub 2018. PMID: 30430444.
- Oh CW, Thorne A, Duke T, Lewis DJ, Talpur R, Duvic M. Waistband mycosis fungoides: A new clinical variant of early-stage disease. Skinmed 17(5):329-32, 2019. e-Pub 2019. PMID: 31782708.
- Kim EJ, Aria AB, Wilmas K, Lewis DJ, Torres-Cabala CA, Nunez C, Dabaja BS, Duvic M. Primary cutaneous CD4+ small- to medium-sized pleomorphic T-cell lymphoproliferative disorder in a pediatric patient successfully treated with low-dose radiation. Pediatr Dermatol 36(1):e23-e26, 2019. e-Pub 2018. PMID: 30548331.
- Aria AB, Wilmas K, Kim EJ, Aung PP, Duvic M. The development of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoproliferative disorder at the site of a melanoma excision scar. Dermatol Online J 24(9), 2018. e-Pub 2018. PMID: 30677830.
- Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M, MAVORIC Investigators. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 19(9):1192-1204, 2018. e-Pub 2018. PMID: 30100375.
- Huang S, Kim EJ, Lewis DJ, Chan WH, Miranda RN, Duvic M. Mycosis fungoides occurring at the site of previous herpes zoster eruption. Australas J Dermatol 59(3):217-219, 2018. e-Pub 2017. PMID: 29280139.
- Lewis DJ, Miranda RN, Oh CW, Hinojosa T, Medeiros LJ, Curry JL, Tetzlaff MT, Torres-Cabala CA, Nagarajan P, Ravandi-Kashani F, Duvic M. Pruritic arthropod bite-like papules in T-cell large granular lymphocytic leukaemia and chronic myelomonocytic leukaemia. Clin Exp Dermatol 43(4):449-453, 2018. e-Pub 2018. PMID: 29423961.
- Gru AA, Kim J, Pulitzer M, Guitart J, Battistella M, Wood GS, Cerroni L, Kempf W, Willemze R, Pawade J, Querfeld C, Schaffer A, Pincus L, Tetzlaff M, Duvic M, Scarisbrick J, Porcu P, Mangold AR, DiCaudo DJ, Shinohara M, Hong EK, Horton B, Kim YH. The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome: A Multi-institutional and International Pathology Study. Am J Surg Pathol 42(6):726-734, 2018. e-Pub 2018. PMID: 29543675.
- Emge DA, Lewis DJ, Aung PP, Duvic M. How to discern folliculotropic mycosis fungoides from follicular mucinosis using a pediatric case. J Cutan Med Surg 22(3):1203475417752366, 2018. e-Pub 2018. PMID: 29318909.
- Duvic M, Bates SE, Piekarz R, Eisch R, Kim YH, Lerner A, Robak T, Samtsov A, Becker JC, McCulloch W, Waksman J, Whittaker S. Responses to Romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2017. PMID: 28853310.
- Lewis DJ, Kim EJ, Duvic M. Image Gallery: Symmetrical whirled eschars on the face in mycosis fungoides. Br J Dermatol 178(3):e224, 2018. PMID: 29595240.
- Chan WH, Lewis DJ, Kim EJ, Aung PP, Duvic M. Generalized morphea/eosinophilic fasciitis overlap after epoxy exposure. JAAD Case Rep 4(2):175-178, 2018. e-Pub 2018. PMID: 29892660.
- Jour G, Aung PP, Merrill ED, Curry JL, Tetzlaff MT, Nagarajan P, Ivan D, Prieto VG, Duvic M, Miranda RN, Torres-Cabala CA. Differential expression of CCR4 in primary cutaneous gamma/delta (γ/δ) T cell lymphomas and mycosis fungoides: significance for diagnosis and therapy. J Dermatol Sci 89(1):88-91, 2018. e-Pub 2017. PMID: 29030090.
- Lewis DJ, Kim YH, Duvic M. Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma. Br J Dermatol 178(1):302-303, 2018. e-Pub 2018. PMID: 28889405.
- Lewis DJ, Duvic M. Important considerations for legislation banning commercial tanning beds among minors. Clin Dermatol 36(1):104-105, 2018. e-Pub 2017. PMID: 29241746.
- Lewis DJ, Holder BB, Duvic M. The "Duvic regimen" for erythrodermic flares secondary to Staphylococcus aureus in mycosis fungoides and Sézary syndrome. Int J Dermatol 57(1):123-124, 2018. e-Pub 2017. PMID: 29152728.
- Emge DA, Lewis DJ, Aung PP, Duvic M. Eosinophilic infiltrate resembling eosinophilic cellulitis (Wells syndrome) in a patient with mycosis fungoides. Dermatol Online J 24(1), 2018. e-Pub 2018. PMID: 29469767.
- Chan WH, Lewis DJ, Hinojosa T, Curry JL, Duvic M. Juvenile mycosis fungoides with large-cell transformation: Successful treatment with psoralen with ultraviolet A light, interferon-alfa, and localized radiation. Pediatr Dermatol 35(1):e13-e16, 2018. e-Pub 2017. PMID: 29159918.
- Wilmas K, Aria A, Torres-Cabala CA, Lu H, Duvic M. Schnitzler syndrome in a patient with a family history of monoclonal gammopathy. Dermatol Online J 24(1), 2018. e-Pub 2018. PMID: 29469761.
- Lewis DJ, Talpur R, Huen AO, Tetzlaff MT, Duvic M. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results. JAMA Dermatol 153(12):1302-1306, 2017. e-Pub 2017. PMID: 28980004.
- Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MB, Curry JL, Rook AH, Abbas HA, Coarfa C, Gunaratne PH, Tsai KY, Flores ER. ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell 29(6):874-888, 2016. PMID: 27300436.
- Zic JA, Ai W, Akilov OE, Carter JB, Duvic M, Foss F, Girardi M, Gru AA, Kim E, Musiek A, Olsen EA, Schieke SM, Shinohara M, Zain JM, Geskin LJ. United States Cutaneous Lymphoma Consortium Recommendations for Treatment of Cutaneous Lymphomas During the COVID-19 Pandemic. J Am Acad Dermatol. e-Pub 2020. PMID: 32305443.
- Ramachandran V, Park KE, Torres-Cabala CA, Duvic M. Second primary malignancies in subcutaneous panniculitis-like T-cell lymphoma: a national database study. Clin Exp Dermatol. e-Pub 2020. PMID: 32359183.
- Ramachandran V, Park KE, Loya A, Duvic M. Second primary malignancies in blastic plasmacytoid dendritic cell neoplasm: a national database study. J Am Acad Dermatol. e-Pub 2020. PMID: 32278799.
- Tran J, Duvic M, Torres-Cabala CA. Lymphomatoid papulosis with a unique T follicular helper-like phenotype. Am J Dermatopathol. e-Pub 2020. PMID: 32568843.
- Ni X, Austin M, Langridge T, Bojaxhi P, Bijani P, Wang X, Duvic M. CD209+ monocyte-derived myeloid dendritic cells were increased in patients with leukemic cutaneous T-cell lymphoma undergoing extracorporeal photopheresis via the CELLEXTM system. Photodermatol Photoimmunol Photomed. e-Pub 2020. PMID: 32187738.
Book Chapters
- Duvic M. Chapter 440: Urticaria, Drug Hypersensitivity Rashes, Nodules and Tumors, and Atrophic Diseases. In: Goldman-Cecil Medicine. 25. Elsevier: Philadelphia, PA, 2683-95, 2018.
- Duvic, M. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma. In: Cutaneous Lymphoma. October. Elsevier: New York, 757-764, 2015.
- Pozadzides J, Duvic M, Pro B. Chapter 9: T-cell lymphomas. In: The MD Anderson Manual of Medical Oncology, 3rd Ed. 3rd. McGraw-Hill, 2014.
- Duvic M. Cutaneous T-cell lymphomas: Mycosis fungoides and Sezary syndrome. In: Lymphoma: Diagnosis and Treatment. Springer: New York, 287-329, 2013.
Books (edited and written)
- Vahquist A, Duvic M. Retinoids and Carotenoids in Dermatology. Ed(s) Taylor & Frances. Taylor & Frances, 2007.
- Werth VP, Duvic M. Dermatologic Clinics on Medical Dermatology. WB Saunders, Inc, 2001.